Tag | Content |
---|---|
UniProt Accession | FYN_HUMAN; P06241; |
Entrez ID | 2534 |
GenBank Protein ID | NM_002037.5; NM_153047.3; NM_153048.3; XM_005266890.3; XM_005266892.3; XM_017010650.1; XM_017010651.1; XM_017010652.1; XM_017010653.1; XM_017010654.1; |
GenBank Nucleotide ID | NP_002028.1; NP_694592.1; NP_694593.1; XP_005266947.1; XP_005266949.1; XP_016866139.1; XP_016866140.1; XP_016866141.1; XP_016866142.1; XP_016866143.1; |
Protein Name | Tyrosine-protein kinase Fyn (EC 2.7.10.2) (Proto-oncogene Syn) (Proto-oncogene c-Fyn) (Src-like kinase) (SLK) (p59-Fyn) |
Gene Name | FYN |
Organism | Homo sapiens |
NCBI Taxa ID | 9606 |
Functional Description | Non-receptor tyrosine-protein kinase that plays a role in many biological processes including regulation of cell growth and survival, cell adhesion, integrin-mediated signaling, cytoskeletal remodeling, cell motility, immune response and axon guidance. Inactive FYN is phosphorylated on its C-terminal tail within the catalytic domain. Following activation by PKA, the protein subsequently associates with PTK2/FAK1, allowing PTK2/FAK1 phosphorylation, activation and targeting to focal adhesions. Involved in the regulation of cell adhesion and moti(view all) |
Sequence (Fasta) | MGCVQCKDKE ATKLTEERDG SLNQSSGYRY GTDPTPQHYP SFGVTSIPNY NNFHAAGGQG 60 LTVFGGVNSS SHTGTLRTRG GTGVTLFVAL YDYEARTEDD LSFHKGEKFQ ILNSSEGDWW 120 EARSLTTGET GYIPSNYVAP VDSIQAEEWY FGKLGRKDAE RQLLSFGNPR GTFLIRESET 180 TKGAYSLSIR DWDDMKGDHV KHYKIRKLDN GGYYITTRAQ FETLQQLVQH YSERAAGLCC 240 RLVVPCHKGM PRLTDLSVKT KDVWEIPRES LQLIKRLGNG QFGEVWMGTW NGNTKVAIKT 300 LKPGTMSPES FLEEAQIMKK LKHDKLVQLY AVVSEEPIYI VTEYMNKGSL LDFLKDGEGR 360 ALKLPNLVDM AAQVAAGMAY IERMNYIHRD LRSANILVGN GLICKIADFG LARLIEDNEY 420 TARQGAKFPI KWTAPEAALY GRFTIKSDVW SFGILLTELV TKGRVPYPGM NNREVLEQVE 480 RGYRMPCPQD CPISLHELMI HCWKKDPEER PTFEYLQSFL EDYFTATEPQ YQPGENL 538 |
|
Database | Annotation |
---|---|
CTD (Curated) (count: 5) | MESH:D002375
; Catalepsy MESH:D015459 ; Leukemia-Lymphoma, Adult T-Cell MESH:D008106 ; Liver Cirrhosis, Experimental MESH:D016411 ; Lymphoma, T-Cell, Peripheral MESH:D013274 ; Stomach Neoplasms |
DisGeNet (Curated) (count: 10) (view all) | C0001969; Alcoholic Intoxication
C0001973; Alcoholic Intoxication, Chronic C0005586; Bipolar Disorder C0007370; Catalepsy C0023493; Adult T-Cell Lymphoma/Leukemia C0023893; Liver Cirrhosis, Experimental |
GWASdb (count: 30) (view all) | rs9320374; Breast cancer; breast cancer
rs6919400; Blood pressure, CVD RF and other traits (body mass index (BMI), waist:hip ratio, renin activity in plasma, aldosterone concentration in plasma, BNP levels in plasma, alcohol consumption); hypertension rs2237255; Response to statin treatment (atorvastatin), change in cholesterol levels; cardiovascular system disease rs9374274; Coronary heart disease; coronary artery disease rs9374274; Insulin Resistance; type 2 diabetes mellitus rs9374274; Insulin-related traits; type 2 diabetes mellitus |
PTM | Modification Sites |
---|---|
Phosphorylation (count: 34) (view all) | 12 QCKDKEATKLTEERD dbPAF
15 DKEATKLTEERDGSL dbPAF 178 GTFLIRESETTKGAY dbPAF 181 LIRESETTKGAYSLS dbPAF 185 SETTKGAYSLSIRDW dbPAF 186 ETTKGAYSLSIRDWD dbPAF |
Acetylation (count: 1) | 427 YTARQGAKFPIKWTA PLMD |
Ubiquitination (count: 10) (view all) | 13 CKDKEATKLTEERDG PLMD
153 AEEWYFGKLGRKDAE PLMD 182 IRESETTKGAYSLSI PLMD 207 VKHYKIRKLDNGGYY PLMD 259 RLTDLSVKTKDVWEI PLMD 295 GTWNGNTKVAIKTLK PLMD |
Malonylation (count: 1) | 427 YTARQGAKFPIKWTA PLMD |
Network | Interaction | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
A | B | Source | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|